Alcohol-use-disorder - Articles - Page 3

The COMBINE Study: A Core Paper in the Treatment of AUD

November 22, 2019

Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This research update summarizes the results of the landmark COMBINE study which evaluated the effectiveness of stand-alone and combined pharmacological and behavioral interventions for treating alcohol use disorder.

Treating Alcohol Use Disorder

October 2, 2019

Albert J. Arias, MD, MS

Albert J. Arias, MD, MS
Associate Professor, Psychiatry Virginia Commonwealth University School of Medicine. Associate Division Chair, Addiction Psychiatry and Addiction Medicine. Dr. Arias has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We have five main medications to offer patients with alcohol use disorder: acamprosate, disulfiram, gabapentin, naltrexone (PO or IM), and topiramate. The combination of naltrexone and gabapentin may work better than either of these two medications alone.

Biomarkers of Alcohol Use

October 2, 2019

The newer biomarkers of alcohol use include carbohydrate-deficient transferrin; ethyl glucuronide and ethyl sulfate; and phosphatidylethanol.

Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 randomized, double-blind, placebo- controlled trial study casts doubt on using gabapentin enacarbil extended-release (GE-XR) (Horizant), an extended-release version of gabapentin, for treatment in patients with alcohol use disorder